TapImmune (TPIV), a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers has announced that it has amended the patient inclusion criteria for its Phase 2 clinical trial of […]
Alexandra Barnes
Dorsey Represents Mayo Clinic’s Venture Applying AI in Drug Development
Dorsey client Mayo Clinic and Cambridge, Massachusetts-based nference recently announced the formation of Qrativ. Qrativ will combine nference’s artificial intelligence (AI) knowledge synthesis platform with Mayo Clinic’s medical expertise and clinical data […]
Soligenix Initiates Phase 3 Trial of Dusquetide for Oral Mucositis in Head & Neck Cancer Patients
Soligenix’s self-described “DOM–INNATE” study has initiated patient enrollment. The late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that patient […]
Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink in Pancreatic Cancer
Avant Diagnostics, Inc. (‘Avant’) (OTC: AVDX), an oncology-focused healthcare technology company commercializing the proprietary Theralink proteomic biomarker platform announced positive clinical utility data, the confirmation of the clinical utility of the Theralink […]
Buying Spree: Chinese FDI in Western healthcare companies
In 2016, Chinese companies invested more than $44B in the United States. The amount of investment has been growing steadily since 2000, increasing substantially each coming year. Over the last 16 years, […]
ImmunoCellular Therapeutics Targeted Cancer Therapies for Glioblastoma
ImmunoCellular is a L.A.-based clinical stage company developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular’s pipeline includes: a Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate […]
Sierra Oncology’s Cancer Therapies Target the DNA Damage Response Network
Sierra Oncology is a clinical stage drug development company advancing targeted DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer. The company’s lead drug candidate, SRA737, is a highly […]
TapImmune Enrolls 50% in Phase 2 Triple Negative Breast Cancer Study
TapImmune Inc, a clinical-stage immuno-oncology company specializing in the development of immunotherapies targeting women’s cancers, announced that it has enrolled 50% (40/80) of the patients in its randomized Phase 2 clinical study […]
